Pharma: Clinic Roundup
Thursday, June 20, 2013
ALK-Abello A/S, of Horsholm, Denmark, reported a positive outcome of the first of two pivotal Phase III trials of its allergy immunotherapy tablet for the treatment of house dust mite-induced respiratory diseases, demonstrating that the treatment has a significant clinical effect in allergic rhinitis.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.